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Abstract
Alzheimer’s disease is a neurodegenerative condition which results in a significant decline in cognitive status. Novel
treatment approaches for Alzheimer’s are sorely needed, as current medications for the disease offer only marginal
clinical benefit. Research has discovered a connection between the pathology of Alzheimer’s and Type 2 Diabetes, two
serious and seemingly unrelated disorders. Clinical studies have shown that Alzheimer’s disease is associated with brain
insulin resistance similar to the pathology of Type 2 Diabetes. This observation has led to the notion that drugs developed for the treatment of Type 2 Diabetes may be beneficial in modifying the cognitive function and pathophysiology of
individuals suffering from Alzheimer’s disease. This paper offers a comprehensive review of the clinical studies demonstrating the potential of using diabetes medications as an effective therapeutic method for the prevention and treatment
of Alzheimer’s disease. Special focus is given towards the metabolic hormones insulin, amylin and leptin.
Introduction
Alzheimer’s and Type 2 Diabetes are two of the most common
diseases afflicting the elderly population today. A 2016 Report
by the Alzheimer’s Association found that of the 5.4 million
Americans with Alzheimer’s, an estimated 5.2 million people
are age 65 and older (Alzheimer’s Association, 2014). Similarly,
the American Diabetes Association reported that in 2012, of
the 29.1 million Americans with Diabetes, an estimated 11.8
million people were age 65 and older (American Diabetes
Association, 2012). The two conditions have traditionally been
treated as independent disorders. However, recent studies linking Alzheimer’s to Type 2 Diabetes have led to the proposal that
Alzheimer be referred to as “Type 3 Diabetes”. Discoveries of
common pathological mechanisms between these two diseases have given rise to novel clinical trials incorporating diabetes
therapies to treat Alzheimer’s disease.

Methods
A variety of literary reviews and research papers on the subject
were collected through use of the PubMed database. Keywords
such as Alzheimer’s disease, insulin resistance and Type 2 Diabetes
were used to search for relevant material. Access to PubMed was
provided by the Touro College online library system.

Pathophysiology of Alzheimer’s and Type 2
Diabetes
Alzheimer’s disease is a neurodegenerative condition, which
results in nerve cell death and tissue loss throughout the brain
(Li, Z et al., 2015). Scans of brains of individuals suffering from
Alzheimer’s demonstrate severe shrinkage of the hippocampus
and cerebral cortex, as well as the enlargement of the ventricles
(Querfurth et al., 2010).
The pathophysiology of Alzheimer’s disease is described by
the amyloid cascade hypothesis. Cleavage of amyloid precursor protein (APP) leads to the formation of the protein amyloid beta. Excessive cleavage of APP coupled with inefficient
removal of amyloid beta can lead to the formation of amyloid
beta plaques in the brain. These plaques damage and destroy

brain cells by blocking cell-to-cell signaling at synapses (Reitz,
2012). Amyloid beta plaques have also been shown to cause
apoptosis. The presence of amyloid plaques in the brain generates the production of harmful oxidative free radicals which in
turn activates the c-Jun N-terminal kinase (JNK) pathway. The
JNK pathway stimulates the transcription of several key target
genes, including the death inducer Fas ligand. The binding of
Fas ligand to its receptor Fas then induces a cascade of events
that lead to caspase activation and ultimately neuronal cell
death. (Yoshiyuki et al., 2001).
The tau protein also plays an important role in Alzheimer’s disease (Lasagna-Reeves CA et al., 2012). This protein is integral
to maintenance of internal support and transport systems between brain cells. Hyperphosphorylation, which is the addition
of phosphate to too many amino acids, leads to the collapse of
tau proteins into twisted strands referred to as neurofibrillary
tangles (Jack et al., 2013). Without the support of the tau protein, the transport system in the brain collapses. Consequently,
essential nutrients are unable to reach brain cells and cell death
ensues (Gong and Iqbal, 2008).
Diabetes is a metabolic disorder which develops when the body
does not make enough insulin or is unable to use insulin effectively. (Yarchoan and Arnold, 2014). If left untreated, diabetes can
cause many complications, including kidney failure, diabetic ketoacidosis, heart disease and stroke (Schnell et al., 2016). Type
2 Diabetes is characterized by an insulin resistant state which
is most commonly caused by obesity (Smith and Kahn, 2016).
In insulin resistance, muscle, fat, and liver cells do not respond
properly to insulin and thus cannot easily absorb glucose from
the bloodstream. As a result, the body needs higher levels of
insulin to help glucose enter cells. The pancreatic beta cells initially increase their insulin output but fail over time to keep up
with the body’s increased demands for insulin. Type 2 diabetes
develops when insulin production is inadequate to overcome
insulin resistance, resulting in the drastic rise in blood glucose
levels (Yarchoan and Arnold, 2014).
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Discovery of Insulin Resistance in Alzheimer’s
Disease
Insulin receptors are widely distributed in brain regions known to
be involved in memory function, including the hippocampus, cerebral cortex and cerebellum (Werther et al., 2015). Clinical studies
have found evidence for central insulin resistance in Alzheimer’s
brains. Post-mortem studies of brain tissues from people with
Alzheimer’s disease have discovered extensive abnormalities in
insulin and insulin-like growth factor signaling mechanisms in
the brain (Steen et al., 2005). A study of post-mortem human
hippocampus Alzheimer’s tissue was done by exposing the tissue
to different concentrations of insulin. This allowed researchers
to study the activation of insulin pathways in the brain tissue of
people with Alzheimer’s compared to the brain tissue of those
with normal cognitive function. In normal brains, activation of
the insulin receptor initiated a signaling cascade which led to the
production of many downstream insulin signaling proteins. The
blunted insulin response observed in the Alzheimer’s brain tissues
was similar to the insulin resistance observed in Type 2 diabetes
peripheral tissues (Talbot et al., 2012).
The formation of amyloid beta plaques has been implicated as
a possible impetus for the removal of insulin receptors in brain
cells. Studies of Alzheimer’s brains have demonstrated that the
binding of amyloid beta oligomers to hippocampal neurons triggers the removal of dendritic insulin receptor substrates from
the outer membrane of the cell (Xie et al., 2002). These studies
prove that elevated amyloid beta levels induce the removal of cell
surface insulin receptors, thereby furthering insulin resistance.
A molecular model has been proposed to explain how the amyloid beta plaques found in Alzheimer’s disease promote insulin
resistance (Dineley et al., 2014). This model is based on the inflammatory pathway observed in Type 2 Diabetes, where inflammatory cytokines play an important role in establishing insulin
resistance. Signaling from the inflammatory cytokine Tumor
Necrosis Factor (TNF) stimulates JNK (Hoeks et al., 2012).
Activation of the JNK pathway by TNF results in serine phosphorylation of the insulin receptor (Zhao et al., 2008). In order
to be activated, phosphorylation of the insulin receptor must
occur at a tyrosine residue. Addition of the phosphate group at
the serine amino acid in individuals with Type 2 Diabetes results
in inhibition of the insulin receptor (Bomfim et al., 2012).
In a similar fashion, inflammatory cytokines induced by the presence of amyloid beta in the brain can lead to insulin resistance in
Alzheimer’s. Recent work suggests that soluble misfolded amyloid beta can induce inflammatory cytokines through an inflammatory pathway known as NF-κB-inducing kinase (NIK). The
resulting inflammatory state induces insulin resistance through
feedback inhibition of the insulin receptor (Carrero et al., 2012).
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In this case the many signaling chemicals produced by the inflammatory pathway stop the activity of the insulin receptor
(Talbot et al., 2012).
Insulin resistance may promote Alzheimer pathology through
several mechanisms. Firstly, abnormal insulin signaling may
promote amyloid beta and hyperphosphorylated tau formation
through the kinase GSK-3. The activity of GSK-3 is normally
regulated through inhibition by the protein AKT, which is an important kinase in the insulin signaling cascade referred to as the
IRS-1 –AKT pathway (Yarchoan and Arnold, 2014). Therefore,
dysfunctional insulin signaling caused by disturbances in the
IRS-1 –AKT pathway leads to increased GSK-3 activity. Studies
of GSK-3 found that its activity increases tau protein phosphorylation (Li, X et al., 2006) and that it is involved in amyloid beta
production (Takashima, 2006).
Abnormal insulin signaling also interferes with memory and
learning pathways. Insulin is a direct regulator of the ERK/MAP
kinase pathway. This pathway is essential to the induction of
longer term potentiation (LTP) and memory consolidation in
the hippocampus (Winder 1999). LTP is responsible for the
maintenance of long term memory, which is the ability to recall
episodes which are not part of the immediate past (Kelleher et
al., 2004). Disruptions of LTP and memory consolidation contribute to the impaired cognitive function typified by Alzheimer’s
disease (Dineley et al., 2014).

Discussion: New Role for Diabetes Drugs as a
Treatment for Alzheimer’s
Given the role of insulin resistance and deficiency in the pathogenesis of Alzheimer’s disease, it is possible that a drug currently prescribed for Type 2 Diabetes may able also be useful for
Alzheimer’s. Various diabetes drugs are under study to test for
their potential activity in Alzheimer’s. This section provides an
overview of the various clinical studies which assess the potential prospects of using the diabetes drugs insulin and amylin,
as well as the weight loss hormone leptin, to treat Alzheimer’s.

Insulin
The administration of exogenous insulin has predictably become
a prime focus of the effort to treat insulin signaling dysfunction
in Alzheimer’s. Clinical trials have demonstrated that insulin administration acutely affects behavior and cognitive performance
in both healthy individuals and those suffering from Alzheimer’s.
A 2001 study assessed the effects of peripherally administered
insulin infusion in non-impaired individuals (Kern et al., 2001).
Two groups were infused with insulin for 6 hours, one at a high
rate and the other at a low rate. Any effects of the insulin administration on blood glucose concentrations were counteracted by constant glucose infusions. Comparison of the results
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of the high rate insulin and low rate insulin treatment groups
indicated an improvement in the cognitive function of the high
rate insulin group. Subjects exposed to higher insulin infusion
rates demonstrated changes in auditory-evoked potentials, had
enhanced memory as evidenced by improved word recall and
improved cognitive flexibility as measured by the Stroop test.
Similar benefits of peripheral insulin administration on cognitive function were observed in individuals with Alzheimer’s. In a
1999 study, Alzheimer’s patients showed improved story recall
and attention during insulin infusion relative to saline infusion
(Craft et al.,2012).
Despite the results of these clinical trials, there are two main
concerns that must be addressed with regards to utilizing peripheral insulin administration as a treatment for Alzheimer’s.
Firstly, peripherally administered insulin cannot bypass the blood
brain barrier in order to enter the central nervous system (CNS)
and is therefore unable to affect and improve brain function.
Secondly, peripheral insulin infusions can induce hypoglycemia.
Hypoglycemia is a condition characterized by abnormally low
blood glucose which can lead to a seizure or unconsciousness
if left untreated. Although hypoglycemia was mitigated by simultaneous glucose infusions in both studies involving peripheral
insulin administration, this solution is highly impractical outside of
a research setting (Yarchoan and Arnold, 2014).
In light of these concerns, intranasal insulin is considered to be
the best method for insulin delivery in Alzheimer clinical trials.
Insulin that is delivered nasally bypasses the blood brain barrier
and is rapidly delivered into the cerebrospinal fluid from where
it can easily enter the CNS (Mao et al., 2016). Additionally, because intranasal insulin is preferentially delivered to the CNS, it
is possible to achieve clinically relevant insulin concentrations
in the CNS without causing systemic hypoglycemia (Yarchoan
and Arnold, 2014).
Pilot clinical trials using intranasal insulin have had successful results.A 2008 clinical trial reported that delivery of intranasal insulin
for 21 days improved story recall, attention and caregiver-rated
functional status in cognitively impaired subjects or individuals with
Alzheimer’s (Reger et al., 2008). In another clinical trial subjects
given insulin spray over a placebo demonstrated improved delayed
memory and cognitive function (Craft et al., 2012).
One study sought to illustrate the underlying mechanisms
through which intranasal insulin ameliorates Alzheimer’s pathology (Mao et al., 2016). APP/PS1 mice possessing the pathological features of Alzheimer’s disease received intranasal insulin
treatments for a total of 6 weeks, while a control group received saline treatments. Tissue samples were harvested from
both groups upon the conclusion of the treatment period.

In order to determine whether intranasal insulin enhances brain
insulin signaling, the respective levels of key components of the
insulin signaling pathway, such as the insulin receptor beta-subunit (IRB) and protein B kinase (AKT), were measured through
Western Blot analysis. Tissue from healthy wild type mice was
also analyzed to serve as a reference marker of normal levels.
The total levels of IRB and AKT were significantly decreased
in the saline treated APP/PS1 mice compared with wild-type
controls. However, the levels of IRB and AKT in the mice which
received intranasal treatment were closer that of the wild-type
mice, indicating that intranasal insulin treatment can partially
protect APP/PS1 mice from brain insulin signaling deficits.
Intranasal insulin was also shown to reduce the activation of
JNK in APP/PS1 mice. Activation of the JNK pathway results
in serine phosphorylation of the insulin receptor and induces
apoptosis. The level of phosphorylation of JNK was significantly
increased in the hippocampus of saline-treated mice compared
with wild-type controls, signifying that intranasal insulin reduces
JNK activation.
Immunohistochemical analysis of the tissue samples measured
the amounts of amyloid beta plaque deposits in the brains of
the APP/PS1 mice. The number of amyloid plaques in the APP/
PS1 insulin-treated mice was significantly reduced in both the
hippocampus and cortex compared to the saline control group.
It was also discovered that the area of amyloid beta plaques
was significantly decreased in both the hippocampus and cortex
of the insulin treated mice. Additionally, quantitative analysis
revealed substantially reduced soluble amyloid beta oligomers
in insulin-treated APP/PS1 mice. This revelation is especially significant considering that soluble amyloid beta oligomers
are considered the most neurotoxic form of amyloid beta.
Enhanced neurogenesis was also observed in the insulin-treated
APP/PS1 mice. It was shown that intranasal insulin significantly
increased levels of DCX, a marker of neurogenesis. The overall
conclusions of the study were that intranasal insulin treatment
improves cognitive deficits, ameliorates defective brain insulin
signaling, strongly reduces amyloid beta plaque formation, inhibits JNK activation and promotes neurogenesis in APP/PS1 mice.
Despite the successful results observed in studies involving
intranasal insulin treatment, there is concern that chronic hyperinsulinemic conditions in the brain may actually promote
brain insulin resistance. Excessive exposure to insulin in mice
has been shown to lead to abnormal phosphorylation of key
components of the insulin signaling pathway, such as AKT and
GSK-3, in a manner consistent with insulin resistance (Kim et
al., 2011). It may therefore be beneficial to explore avenues
of diabetes treatments which restore the byproducts of insulin
signaling without directly affecting insulin levels.
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Amylin
Amylin is a metabolic hormone which is co-secreted with insulin by pancreatic beta cells (Adler et al., 2014). Amylin’s systemic
effects in diabetic patients include the lowering of blood glucose
levels through delayed gastric emptying, increased satiety, and
decreased secretion of glucagon, which is an antagonist of insulin (Yarchoan and Arnold, 2014).
Amylin’s signaling activity has the potential to alleviate the
detrimental effects of insulin resistance in Alzheimer’s disease. Amylin binds to independent receptors in the brain to
activate signaling pathways that converge with insulin signaling.
Amylin activates the production of the protein AKT, which is
needed for the proper regulation of GSK-3, a protein which
can lead to increased production of amyloid beta plaques and
hyper phosphorylated tau (Moon et al., 2011). Amylin is also
a known modulator of the ERK signaling cascade, a pathway
significant in the maintenance of long term memory and memory consolidation (Adler et al., 2014). An advantage of using
amylin as a medication is that it poses no risk of hyperinsulinemia, as it can activate the insulin pathway without interfering
with the concentration of insulin in the body (Yarchoan and
Arnold, 2014).
One study investigated the potential outcomes of using amylin
as a treatment for Alzheimer’s. The first part of the study compared plasma human amylin levels between individuals with
Alzheimer’s or mild cognitive impairment and individuals with no
cognitive impairments (Adler et al., 2014). The results showed
significantly lower amylin levels among subject with Alzheimer’s
and mild cognitive impairments compared to individuals with no
cognitive deficits. With this correlation between amylin levels
and cognitive function established, a follow-up study was conducted in order to investigate the effects of amylin administration on Alzheimer’s pathology. A senescence-accelerated prone
(SAMP8) mouse was selected as a model of Alzheimer’s related
dementia, because it displays multiple features known to occur
early in the pathogenesis of Alzheimer’s including cortical atrophy, amyloid beta alterations, tau phosphorylation and severe
deficits of learning and memory. The SAMP8 mice were treated
with either amylin or saline infusions for a total of 5 weeks. Due
to the tendency of amylin to aggregate into brain plaques in its
natural form, a soluble analog of amylin called pramlintide was
used in the study.
The object recognition test was performed on the mice during
the last week of the 5-week treatment period in order to assess
the effects of amylin on cognitive function. The object recognition test is a behavioral assay that is based upon the natural
tendency of mice to investigate a novel object instead of a familiar one, as well as their innate tendency to restart exploring
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when they are presented with a novel environment. The mice
were placed in an open field box filled with different objects of
various shapes and sizes. After a series of trials, during which
the mice habituated to the configuration and properties of
the different objects, some of the objects were replaced with
new ones to evaluate novel object recognition. The pramlintide-treated SAMP8 mice spent a greater proportion of time
exploring the novel objects as compared with the familiar objects, whereas the saline-treated SAMP8 mice did not differ in
time spent with the novel and familiar objects. The behavior of
the pramlintide-treated mice signified a marked improvement in
their cognitive function.
Hippocampal tissue samples were harvested from the SAMP8
mice in order to assess the effect of amylin on oxidative
stress, an important pathologic feature of Alzheimer’s. The
protein levels found in the pramlintide-treated SAMP8 mice
indicated a decrease in the molecular markers associated
with oxidative stress and neuro-inflammation. The pramlintide-treated SAMP8 mice had significantly decreased expression of the protein H0-1 in the hippocampus compared with
saline-treated mice. HO-1 is a cellular stress protein that is
activated during high oxidative stress and inflammatory states,
and is also known to be increased in the cerebral cortex of
Alzheimer’s brains. The pramlintide-treated SAMP8 mice also
had decreased levels of the lipid peroxidation adduct HNE
and the enzyme COX-2. HNE is a protein that is known to
be an early and abundant cellular stress marker in Alzheimer’s
brains, while C0X-2 is a classic marker of inflammation which
is increased in Alzheimer’s brains.
The pramlintide-treated SAMP8 mice expressed high amount of
proteins associated with synaptic activity and dendritic growth.
Amylin was found to increase expression of hippocampal synapsin I, a protein located in neuronal synaptic vesicles that is
involved in synapse formation, neurotransmitter release, and
learning and memory. A robust increase in CDK5 was also observed in the hippocampus of the pramlintide-treated SAMP8
mice. CDK5 is a kinase which plays an intimate role in synaptic
plasticity, learning and memory in adult brains.
The overall conclusions of the study were that chronic infusion
of amylin in SAMP8 mice was found to improve memory performance in object recognition tests, increase neural synaptic
activity and decrease inflammatory markers in the hippocampus. Amylin treatment improved both the cognitive status and
Alzheimer’s pathology features of the SAMP8 mice.
Another study also assessed the results of amyloid treatment
on behavioral impairment and brain amyloid pathology in
mouse models of Alzheimer’s disease (Zhu et al., 2015). The
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study utilized 5XFAD Alzheimer mice which exhibit significant
neuron loss. The 5XFAD mice were treated with intraperitoneal injections of either pramlintide or saline once daily for 10
weeks.
The 5XFAD mice were tested for improvements in cognitive
functions by going through a Morris water maze. The Morris
water maze test is used to determine hippocampal spatial
memory deficits. The test consisted of placing the rodent in a
circular tank filled with cloudy water, which is used to motivate
the animal to escape the water by swimming to a hidden platform located in one quadrant of the pool. Over several days the
rodent learnt to find the hidden platform by using spatial cues,
such as posters or taped objects strategically placed on the walls
outside of the water maze, in the testing room. The pramlintide
treatment improved the performance of the mice in the Morris
water maze test, reducing the time necessary for memory acquisition and retention during maze training as compared to
the saline-treated control group. The improved performance of
the pramlintide-treated groups over the saline-treated groups
in the Morris water maze test demonstrated that peripheral
treatments with pramlintide improves learning and memory in
the 5XFAD mice.
Pramlintide treatment was shown to have an effect on amyloid beta levels, one of the prime pathological hallmarks of
Alzheimer’s. Immunoassays of brain tissue from the 5XFAD
mice revealed that pramlintide-treated 5XFAD mice experience
a reduction in both size and intensity of amyloid beta plaques
in the cortex, hippocampus and thalamus and had decreased
numbers of amyloid beta plaques in all areas of the brain with
the exception of the hippocampus. Furthermore, comparison
of amyloid beta serum levels from before and after the intraperitoneal pramlintide infusion revealed a significant increase in
serum amyloid beta after the infusion. These results indicate
that pramlintide enhances the removal of amyloid beta from the
brain and its transfer into the blood.
The successful outcomes of these separate studies assessing the
effect of pramlintide treatment on different Alzheimer’s mouse
models indicate that amylin has potential to become a promising new avenue for the treatment of Alzheimer’s. Amylin was
shown to improve cognitive function, reduce oxidative stress
markers, increase synaptic activity and enhance clearance of amyloid beta from the brain.

Leptin
Leptin is a chemical produced by fat tissues which activates the
central nervous system to regulate food consumption and energy expenditure (Oomura et al., 2006). Although leptin has traditionally been studied in the context of obesity, recent studies

have examined its neurological effects. Leptin receptors are
highly expressed in areas of the brain that are involved in learning and memory, such as the hippocampus (Li, X-L et al., 2002).
A study was designed in order to assess leptin’s role in the
regulation of hippocampal functions and the control of learning and memory processes (Li, X-L et al., 2002). The study
focused on leptin receptor-deficient mice. The behavioral
and molecular data obtained from the leptin receptor-deficient mice was compared against a positive leptin receptor
control group. Both groups of mice were put through the
Morris water maze task. The leptin receptor-deficient mice
swam greater distance than their positive controls before
they found and climbed onto the hidden platform. When
the platform was removed, the leptin receptor-deficient mice
crossed the original platform location fewer times than the
positive control group. The hippocampus was removed from
the leptin receptor-deficient rodents and the control group.
Electrophysiological analysis of the hippocampal tissue of the
leptin receptor-deficient mice showed impairments of long
term potentiation (LTP) and long term depression (LTD). The
decreased cognitive behavior and impaired LTP and LTD processing observed in the leptin receptor-deficient mice support
the conclusion that leptin enhances LTP and regulates mechanism involved in both learning and memory
Leptin also appears to regulate a number of defining features
of Alzheimer’s disease. AMP- dependent kinase (AMPK) is
known to regulate glycogen synthase kinase-3B (GSK-3B), a
kinase which is crucial in the regulation of tau phosphorylation
(Nikolaos et al., 2009). It has been shown that leptin directly
activates AMPK and thereby possesses the ability to modulate
tau phosphorylation (Yu et al., 2004). Leptin also facilitates the
uptake of amyloid beta complexes via its regulation of the lipoprotein receptor-like protein (Fewlass et al., 2004). Thus, leptin’s
activity directly affects the regulation of amyloid beta uptake
and tau phosphorylation, two of the impaired pathophysiological
features of Alzheimer’s disease.
One study assessed the effects of leptin treatment on CRND8
Alzheimer’s mouse models (Greco et al., 2010). The CRND8
mice received daily treatments of leptin for a total of 8 weeks
with a control group receiving saline infusions. Leptin-treated
mice spent statistically more time with the novel object compared to the saline-treated control group during the object
recognition test, indicating an improvement in working memory
performance after leptin treatment. Analysis of brain tissue from
the CRND8 mice revealed that the leptin-treated group had
reduced amyloid beta levels in both brain and serum. Staining
of the brain tissue for amyloid fibers showed a significant decrease in amyloid burden in the hippocampus of the leptin
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treated CRND8 mice, which was associated with a decrease
in the average size of amyloid plaques. There was no significant
increase in the levels of the inflammatory molecule C-reactive
protein, tumor necrosis factor or cortisol in the plasma of the
leptin-treated group compared to the saline-treated group, indicating that leptin does not induce an inflammatory reaction.
The results of the study fully support the ability of leptin to
ameliorate Alzheimer’s like pathological pathways, strengthening
leptin’s potential of becoming a novel therapeutic treatment for
Alzheimer’s disease.

Synergistic Effects of Amylin and Leptin
Leptin and amylin activate overlapping signaling cascades and
ultimately converge on the insulin signaling pathway by activating AKT and increasing insulin sensitivity (Yarchoan and Arnold,
2014). Recent studies have indicated that leptin and amylin signaling appear to have synergistic properties.
One study profiled hypothalamic neurons in order to determine the effects of amylin and leptin on hypothalamic activity (Li,
Z et al., 2015). It was discovered that hypothalamic expression
of lapp, a precursor to amylin, was markedly decreased in mice
with mutations in the gene regulating the production of amylin,
but was normalized after infusions of leptin. The decrease of
amylin expression in mice that had mutated leptin genes showed
that hypothalamic amylin is a neuropeptide that is leptin regulated. Additionally, AC187, an amylin antagonist, was found to blunt
the activity of leptin and decreased its effects on neurons in the
hypothalamus. The presence of the amylin antagonist significantly inhibited the effects of leptin on both leptin depolarizing
and hyperpolarizing neurons. The ability of an amylin antagonist to blunt the response of leptin suggests that amylin can
modulate leptin’s effects. Leptin and amylin were also found to
have synergistic effects on hypothalamic neurons. Patch clamp
recordings demonstrated that the presence of either leptin or
amylin elicited similar excitatory and inhibitory effects on hypothalamic neurons. Leptin excited 65% and inhibited 35% of
the neurons, while amylin excited 62% and inhibited 38%. The
significant correlation between the effects of individual neurons
exposed to both treatments indicates that amylin depolarizes
the same neurons that are depolarized by leptin and hyperpolarizes the same neurons that are hyperpolarized by leptin. This
suggests that the response of the neuron would be amplified
upon simultaneous presentation of amylin and leptin.
The synergistic potential of these two treatments has been
explored with regards to treating obesity. Stand-alone obesity treatments have proven unsuccessful because diet-induced
obese (DIO) rats and obese humans are only minimally responsive to even high pharmacological doses. Nonetheless, amylin
possesses the ability to heighten leptin’s effects. For this reason,
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one study found that doses of exogenous leptin that was highly effective in lean rats had minimal effects on weight or food
intake in DIO rats. However, the results of the study showed
that administration of amylin together with leptin resulted in a
synergistic, fat-specific reduction in body weight in two independent experiments (Roth et al., 2008).
In light of this discovery, a clinical trial was designed in order to
evaluate the weight-lowering effect of combined amylin/leptin
(using pramlintide/mertreleptin) treatment in human obesity.
A 24-week, randomized, double-blind, study was conducted in
obese or overweight subjects. Subjects receiving pramlintide/
metreleptin lost almost 13% of their initial body weight over
24 weeks, compared with only ~8% in subjects receiving either pramlintide or metreleptin. Towards the end of the study,
weight loss plateaued in subjects treated with monotherapy,
but not in subjects treated with the combination. The overall
results of the study showed that weight loss caused by the
combination of leptin and amylin in humans was greater than
the additive weight loss of each drug used alone (Ravussin et
al., 2009).
Thus far, there have been no studies to examine the efficacy of
combination therapy of leptin and amylin to treat Alzheimer’s.
The successful results observed in weight loss clinical trials suggest that even greater improvements in memory in Alzheimer’s
patients may be possible by using amylin and leptin as a combined therapy.

Conclusion
The discovery of insulin resistance in Alzheimer’s has given
way to a growing interest in restoring insulin signaling in
Alzheimer’s with therapeutic agents originally developed for
the treatment of Type 2 Diabetes. Intranasal insulin, amylin
and leptin are examples of hormones typically associated with
obesity and diabetes which have shown promise for treating
Alzheimer’s disease. An advantage of using amylin and leptin
as medications for Alzheimer’s is that unlike with insulin, treatment using these hormones pose no risk of inducing hyperinsulinemia, as they activate the products of the insulin signaling
pathway without interfering with the concentration of insulin
in the body. Furthermore, weight loss studies have discovered
that amylin and leptin are synergistic substances which produce significantly enhanced results when used in combination.
This unique synergy suggests that achieving even greater improvements in memory may be possible by using amylin and
leptin as a combined therapy for Alzheimer’s. Further research
will need to take place before the proposed combined therapy
can be tested in a clinical trial and ultimately be distributed
pharmaceutically.
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